Omeprazole and Clopidogrel Interaction

Introduction to Guideline Recommendations

The American College of Cardiology and American Heart Association guidelines suggest that the expert consensus does not prohibit PPI use in appropriate clinical settings, but emphasizes reevaluating the need for starting or continuing omeprazole in patients taking clopidogrel, with a strength of evidence based on randomized trials and observational studies 1, 3, 4
The FDA recommends avoiding concomitant use of omeprazole with clopidogrel due to omeprazole's inhibition of CYP2C19, which reduces clopidogrel's conversion to its active metabolite, although this is based on pharmacodynamic studies rather than clinical outcomes 1, 2

The COGENT randomized trial of 3,627 patients found no difference in cardiovascular outcomes (HR: 1.02, 95% CI: 0.68-1.44) between clopidogrel plus omeprazole versus clopidogrel plus placebo, while gastrointestinal bleeding was reduced by 60%, providing moderate-quality evidence for the safety of this combination in patients requiring gastroprotection 1, 2, 5
The study had important limitations, including early termination before reaching planned enrollment, a low number of cardiovascular events (55 versus 54 events), and wide confidence intervals that do not exclude a clinically important increase in risk up to 44%, which reduces the strength of evidence for the findings 1, 2

Laboratory studies consistently show that omeprazole reduces clopidogrel's antiplatelet effect, with omeprazole significantly decreasing platelet inhibition measured by VASP and other platelet aggregation assays, although the clinical significance of this interaction is uncertain 1, 2
Clinical outcome studies show mixed results, with the PRINCIPLE-TIMI 44 and TRITON-TIMI 38 trials finding that PPI treatment attenuated clopidogrel's pharmacodynamic effects but did not affect clinical outcomes for cardiovascular events, providing low-quality evidence for the lack of a significant interaction 1, 5

When a patient on clopidogrel requires gastroprotection, the American College of Cardiology recommends considering alternative PPIs, such as pantoprazole, which has minimal CYP2C19 inhibition and was not associated with recurrent MI in patients receiving clopidogrel, based on moderate-quality evidence from observational studies 1, 5
H2 receptor antagonists, such as ranitidine or famotidine, may be considered for patients requiring acid suppression, as the FDA notes no evidence that H2 blockers or antacids interfere with clopidogrel's antiplatelet activity, although this is based on limited evidence 1, 2, 3, 4

Patients at highest risk for GI bleeding who may benefit from omeprazole despite the interaction include those with a history of prior GI bleeding or peptic ulcer disease, concurrent use of aspirin, anticoagulants, corticosteroids, or NSAIDs, although the strength of evidence for this recommendation is low 2

The American College of Cardiology recommends not automatically prescribing omeprazole with clopidogrel without assessing individual bleeding risk, as many patients receive PPIs unnecessarily, based on moderate-quality evidence from observational studies 1, 3
The American Heart Association recommends not assuming all PPIs have the same interaction profile, as omeprazole and esomeprazole have the strongest CYP2C19 inhibition, although the clinical significance of this difference is uncertain 1